摘要
原文 | 英語 |
---|---|
頁(從 - 到) | 798-803 |
頁數 | 6 |
期刊 | Journal of Surgical Oncology |
卷 | 104 |
發行號 | 7 |
DOIs | |
出版狀態 | 已發佈 - 十二月 2011 |
指紋
ASJC Scopus subject areas
- Surgery
- Oncology
引用此文
Relationship of interleukin-8 gene polymorphisms with hepatocellular carcinoma susceptibility and pathological development. / Chien, Ming Hsien; Yeh, Chao Bin; Li, Yi Ching; Wei, Lin Hung; Chang, Jer Hwa; Peng, Yu Ting; Yang, Shun Fa; Kuo, Wu Hsien.
於: Journal of Surgical Oncology, 卷 104, 編號 7, 12.2011, p. 798-803.研究成果: 雜誌貢獻 › 文章
}
TY - JOUR
T1 - Relationship of interleukin-8 gene polymorphisms with hepatocellular carcinoma susceptibility and pathological development
AU - Chien, Ming Hsien
AU - Yeh, Chao Bin
AU - Li, Yi Ching
AU - Wei, Lin Hung
AU - Chang, Jer Hwa
AU - Peng, Yu Ting
AU - Yang, Shun Fa
AU - Kuo, Wu Hsien
PY - 2011/12
Y1 - 2011/12
N2 - Background and Objectives Hepatocellular carcinoma (HCC) is one of the most frequent malignant neoplasms worldwide, and the second leading cause of death from cancer in Taiwan. Interleukin-8 (IL-8) is an angiogenic chemokine with important roles in the development and progression of many human malignancies including HCC. This study investigates the effects of single-nucleotide polymorphisms (SNPs) in the IL-8 gene on the susceptibility and clinicopathological characteristics of HCC. Methods One hundred thirty-one HCC patients and 340 control subjects were analyzed for four IL-8 SNPs (-251 T/A, +781 C/T, +1633 C/T, and +2767 A/T) using PCR-RFLP genotyping analysis. Results After adjusting for other confounders, results show that individuals with the IL-8 +781 T/T polymorphic genotype had a significantly lower risk of developing HCC than those with the wild-type (C/C) genotype (AOR = 0.346; 95% CI: 0.132-0.909). Multiple regression analysis showed that the presence of T/A or A/A at IL-8 -251 may indicate higher potential risk of hepatitis B infection (AOR = 2.847; 95% CI: 1.083-8.656). Additionally, these four IL-8 SNPs did not associate with liver-related clinicopathological markers in serum. Conclusions Genetic polymorphism at IL-8 +781 is an important factor in determining susceptibility to HCC in the Taiwanese population. J. Surg. Oncol. 2011; 104:798-803. © 2011 Wiley Periodicals, Inc.
AB - Background and Objectives Hepatocellular carcinoma (HCC) is one of the most frequent malignant neoplasms worldwide, and the second leading cause of death from cancer in Taiwan. Interleukin-8 (IL-8) is an angiogenic chemokine with important roles in the development and progression of many human malignancies including HCC. This study investigates the effects of single-nucleotide polymorphisms (SNPs) in the IL-8 gene on the susceptibility and clinicopathological characteristics of HCC. Methods One hundred thirty-one HCC patients and 340 control subjects were analyzed for four IL-8 SNPs (-251 T/A, +781 C/T, +1633 C/T, and +2767 A/T) using PCR-RFLP genotyping analysis. Results After adjusting for other confounders, results show that individuals with the IL-8 +781 T/T polymorphic genotype had a significantly lower risk of developing HCC than those with the wild-type (C/C) genotype (AOR = 0.346; 95% CI: 0.132-0.909). Multiple regression analysis showed that the presence of T/A or A/A at IL-8 -251 may indicate higher potential risk of hepatitis B infection (AOR = 2.847; 95% CI: 1.083-8.656). Additionally, these four IL-8 SNPs did not associate with liver-related clinicopathological markers in serum. Conclusions Genetic polymorphism at IL-8 +781 is an important factor in determining susceptibility to HCC in the Taiwanese population. J. Surg. Oncol. 2011; 104:798-803. © 2011 Wiley Periodicals, Inc.
KW - genetic polymorphism
KW - hepatocellular carcinoma
KW - interleukin-8
UR - http://www.scopus.com/inward/record.url?scp=80255124785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80255124785&partnerID=8YFLogxK
U2 - 10.1002/jso.22037
DO - 10.1002/jso.22037
M3 - Article
C2 - 21780129
AN - SCOPUS:80255124785
VL - 104
SP - 798
EP - 803
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
SN - 0022-4790
IS - 7
ER -